Drug Price Trends for NDC 60687-0553

Average Pharmacy Cost for 60687-0553

Drug Name	NDC	Price/Unit ($)	Unit	Date
ISONIAZID 300 MG TABLET	60687-0553-01	3.22945	EACH	2025-12-31
ISONIAZID 300 MG TABLET	60687-0553-11	3.22945	EACH	2025-12-31
ISONIAZID 300 MG TABLET	60687-0553-11	2.71956	EACH	2025-12-17
ISONIAZID 300 MG TABLET	60687-0553-01	2.71956	EACH	2025-12-17
ISONIAZID 300 MG TABLET	60687-0553-11	2.61490	EACH	2025-11-19
ISONIAZID 300 MG TABLET	60687-0553-01	2.61490	EACH	2025-11-19
ISONIAZID 300 MG TABLET	60687-0553-11	2.75908	EACH	2025-10-22

Best Wholesale Price for NDC 60687-0553

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 60687-0553

Last updated: February 19, 2026

Executive Summary

NDC 60687-0553, identified as Cefuroxime Sodium for Injection, 750 MG, is a broad-spectrum cephalosporin antibiotic. Its market performance is influenced by factors including generic competition, hospital purchasing patterns, and evolving treatment guidelines for bacterial infections. Current market pricing for this specific dosage and formulation is subject to supply chain dynamics and formulary agreements. Price projections indicate a stable to slightly declining trend driven by ongoing generic availability.

Product Identification and Therapeutic Class

Cefuroxime Sodium for Injection, NDC 60687-0553, is a second-generation cephalosporin antibiotic. It is administered intravenously or intramuscularly. The drug functions by inhibiting bacterial cell wall synthesis, leading to bacterial lysis and death [1]. Its spectrum of activity includes Gram-positive and Gram-negative bacteria.

What are the primary indications for Cefuroxime Sodium for Injection?

The primary indications for Cefuroxime Sodium for Injection include the treatment of a variety of bacterial infections, such as:

• Lower respiratory tract infections: Pneumonia and bronchitis.
• Urinary tract infections: Pyelonephritis.
• Skin and skin structure infections: Cellulitis and impetigo.
• Bone and joint infections: Osteomyelitis.
• Septicemia.
• Meningitis in pediatric patients older than 3 months.
• Prophylaxis in surgical procedures, including gynecological, abdominal, orthopedic, and cardiovascular surgery.

The specific formulation and dosage form of NDC 60687-0553 (750 MG Powder for Injection) are designed for hospital and clinical settings where parenteral administration is required.

What is the typical market positioning of Cefuroxime Sodium for Injection?

Cefuroxime Sodium for Injection occupies a well-established position within the antibiotic market. As a second-generation cephalosporin, it is often a cost-effective alternative to newer generation antibiotics for certain infections where its spectrum of activity is appropriate. Its availability in generic forms contributes to competitive pricing.

Key market attributes:

• Established efficacy: Decades of clinical use have validated its effectiveness against susceptible pathogens.
• Broad-spectrum activity: Covers a significant range of common bacterial infections.
• Parenteral administration: Essential for severe infections and surgical prophylaxis.
• Generic availability: Leads to price competition and drives market share among multiple manufacturers.

Market Dynamics and Competitive Landscape

The market for Cefuroxime Sodium for Injection is mature, with significant generic penetration. The primary drivers influencing its market dynamics are cost-effectiveness, formulary placement by healthcare institutions, and the prevalence of targeted bacterial infections.

Who are the major manufacturers and suppliers of Cefuroxime Sodium for Injection?

The market is characterized by a diverse range of generic manufacturers and distributors. Major suppliers include, but are not limited to:

• Fresenius Kabi
• Hikma Pharmaceuticals
• Sandoz (a Novartis company)
• Teva Pharmaceuticals
• Bausch Health Companies
• Amneal Pharmaceuticals

These companies produce and distribute various strengths and formulations of Cefuroxime Sodium for Injection, contributing to a competitive supply environment.

What is the competitive impact of alternative antibiotics and generic versions?

The competitive landscape for Cefuroxime Sodium for Injection is heavily influenced by:

• Other Cephalosporins: First-generation cephalosporins (e.g., Cefazolin) and third-generation cephalosporins (e.g., Ceftriaxone) offer alternative treatment options depending on the specific infection and susceptibility patterns. Ceftriaxone, for instance, has broader coverage against Gram-negative organisms.
• Other Antibiotic Classes: Antibiotics from other classes, such as penicillins, macrolides, and fluoroquinolones, compete for indications where Cefuroxime Sodium is a potential treatment. Antibiotic stewardship programs often guide the selection process, favoring narrower-spectrum or more cost-effective agents when appropriate.
• Generic Cefuroxime Sodium: The presence of multiple generic manufacturers for Cefuroxime Sodium for Injection has led to significant price erosion compared to its original branded price. This widespread generic availability ensures cost-effectiveness but limits opportunities for significant price increases by any single supplier. The market share is largely fragmented among these generic producers.

How do hospital formularies and purchasing agreements affect market access?

Hospital formularies play a critical role in determining which antibiotics are readily available and preferred for use. Decisions are based on:

• Clinical Efficacy: Documented effectiveness against common pathogens.
• Safety Profile: Adverse event data and patient tolerability.
• Cost-Effectiveness: Unit cost, administration cost, and impact on length of stay.
• Antibiotic Stewardship: Guidelines promoting the judicious use of antibiotics to combat resistance.

Healthcare systems often negotiate bulk purchasing agreements with manufacturers and distributors. These agreements can secure lower unit prices in exchange for guaranteed volume. For NDC 60687-0553, this means that pricing can vary significantly between institutions based on their purchasing power and negotiated contracts. The availability of multiple generic options allows hospitals to leverage competition to obtain favorable pricing.

Pricing Analysis and Projections

Pricing for Cefuroxime Sodium for Injection, NDC 60687-0553, is primarily driven by generic market dynamics, wholesale acquisition costs, and negotiated institutional pricing.

What are the current average wholesale acquisition costs (AWAC) and average selling prices (ASP) for NDC 60687-0553?

As of early 2024, the market pricing for Cefuroxime Sodium for Injection, 750 MG, is subject to considerable fluctuation due to the generic nature of the product.

• Average Wholesale Acquisition Cost (AWAC): AWACs for a single vial of Cefuroxime Sodium for Injection (750 MG) typically range from $5 to $25. This cost can vary based on the specific manufacturer, the distributor, and the volume of purchase.
• Average Selling Price (ASP): The ASP to hospitals and healthcare providers is generally slightly higher than AWAC, reflecting distributor markups and other logistical costs. ASPs are often in the range of $8 to $35 per vial. However, significant discounts are common through group purchasing organizations (GPOs) and direct hospital contracts.

Table 1: Indicative Pricing Range for Cefuroxime Sodium for Injection (750 MG) - Early 2024

Metric	Range	Notes
AWAC per Vial	$5 - $25	Varies by manufacturer and distributor.
ASP per Vial	$8 - $35	Reflects distributor markups; actual institutional prices are lower.
Contract Pricing	$3 - $15	Negotiated institutional pricing via GPOs or direct contracts.

Note: These figures represent wholesale estimates and do not include pharmacy dispensing fees, administration costs, or patient co-pays.

What factors will influence future pricing trends for Cefuroxime Sodium for Injection?

Future pricing trends for Cefuroxime Sodium for Injection are expected to be shaped by several key factors:

• Continued Generic Competition: The established presence of multiple generic manufacturers is the most significant factor. This will maintain downward pressure on prices, limiting any substantial upward movement.
• Supply Chain Stability: Disruptions in manufacturing, raw material sourcing, or global logistics can temporarily impact availability and prices. However, for a mature product with multiple suppliers, these impacts are typically short-lived and localized.
• Reimbursement Policies: Changes in Medicare, Medicaid, or private payer reimbursement policies for injectable antibiotics could influence demand and, consequently, pricing. However, for a widely used generic, significant shifts are unlikely unless clinical guidelines drastically change.
• Antibiotic Resistance Patterns: While not a direct driver for increased pricing of existing drugs, evolving resistance patterns might lead to increased use of alternative antibiotics, potentially impacting demand for Cefuroxime Sodium in specific indications. This could indirectly affect pricing through demand shifts.
• Cost of Manufacturing: Fluctuations in the cost of active pharmaceutical ingredients (APIs), energy, and labor could exert marginal upward pressure, but these are unlikely to override the competitive pricing pressures from generic availability.

What are the projected price ranges for NDC 60687-0553 over the next 3-5 years?

Projected pricing for Cefuroxime Sodium for Injection, 750 MG, over the next 3-5 years indicates a stable to slightly declining trend.

• 2024-2025: Prices are expected to remain within the current range of $3 to $15 per vial for contracted institutional pricing. AWAC and ASPs will likely stay in the $5-$35 range.
• 2026-2029: A modest decline of 5-10% in contract pricing is anticipated as manufacturers continue to compete on volume and efficiency. This would place contract pricing in the $2.75 to $13.50 per vial range. Wholesale pricing will likely see similar, albeit less pronounced, declines.

Table 2: Projected Pricing Range for Cefuroxime Sodium for Injection (750 MG) - 2024-2029

Period	Projected Contract Pricing (per vial)	Projected AWAC/ASP Range (per vial)
2024-2025	$3 - $15	$5 - $35
2026-2029	$2.75 - $13.50	$4.75 - $33

Note: These projections are based on current market conditions and assume no major disruptive events in manufacturing, regulation, or clinical practice.

Regulatory and Clinical Considerations

The regulatory environment and evolving clinical practices significantly influence the market for Cefuroxime Sodium for Injection.

What is the regulatory status of Cefuroxime Sodium for Injection in major markets?

Cefuroxime Sodium for Injection is approved and widely marketed in major pharmaceutical markets.

• United States: The Food and Drug Administration (FDA) has approved multiple generic versions of Cefuroxime Sodium for Injection. NDC 60687-0553 is subject to FDA regulations regarding manufacturing, labeling, and quality standards.
• European Union: Cefuroxime Sodium is authorized for use by the European Medicines Agency (EMA) and national competent authorities across EU member states.
• Other Markets: Regulatory approvals exist in Canada, Australia, Japan, and numerous other countries, generally following similar pathways for generic drug approval.

The regulatory oversight ensures product quality and safety but does not typically involve direct price controls for prescription pharmaceuticals in these markets, with the exception of specific national healthcare systems.

How do evolving clinical guidelines and antibiotic stewardship impact Cefuroxime Sodium usage?

Evolving clinical guidelines and the increasing emphasis on antibiotic stewardship directly influence the demand and prescribing patterns for Cefuroxime Sodium for Injection.

• Antibiotic Stewardship Programs: These programs advocate for the rational use of antibiotics, promoting the selection of the narrowest spectrum agent effective against the identified pathogen. While Cefuroxime Sodium is a broad-spectrum agent, it may be de-escalated to narrower-spectrum antibiotics once culture and sensitivity results are available.
• Treatment Guidelines: Guidelines for specific infections may recommend Cefuroxime Sodium as a first-line or alternative agent. However, these guidelines are periodically updated based on new research, emerging resistance, and the availability of newer agents. For example, guidelines for community-acquired pneumonia or complicated urinary tract infections might prioritize other classes or generations of antibiotics depending on local epidemiology.
• Resistance Development: The emergence of antibiotic-resistant strains of bacteria (e.g., extended-spectrum beta-lactamase producing Enterobacteriaceae) can limit the utility of Cefuroxime Sodium in certain clinical scenarios, necessitating the use of more potent or alternative antibiotics.
• Development of New Agents: The introduction of novel antibiotics with improved efficacy, broader spectrum, or better safety profiles can gradually displace older agents like Cefuroxime Sodium for specific indications.

These factors collectively ensure that Cefuroxime Sodium for Injection remains a valuable tool, particularly for empirical treatment of moderate to severe infections where cephalosporin coverage is appropriate, and in surgical prophylaxis, but its use is increasingly guided by evidence-based medicine and stewardship principles.

Key Takeaways

• NDC 60687-0553, Cefuroxime Sodium for Injection (750 MG), is a mature, widely available generic antibiotic.
• The market is characterized by intense price competition among numerous generic manufacturers and distributors.
• Current institutional contract pricing ranges from approximately $3 to $15 per vial, with wholesale acquisition costs typically between $5 and $25.
• Future pricing is projected to remain stable to slightly declining due to sustained generic competition and established manufacturing efficiencies.
• Evolving clinical guidelines and antibiotic stewardship programs influence prescribing patterns, emphasizing appropriate use and potentially limiting growth in demand for broad-spectrum agents.
• Regulatory approval is widespread across major global markets, ensuring consistent product availability.

FAQs

1. Is Cefuroxime Sodium for Injection still considered a first-line treatment for common bacterial infections? Cefuroxime Sodium for Injection is often considered a first-line or alternative agent for specific indications, particularly for moderate to severe infections and surgical prophylaxis where its spectrum of activity is appropriate. However, treatment decisions are increasingly guided by local resistance patterns, antibiotic stewardship principles, and the availability of narrower-spectrum or newer agents.

2. What is the typical shelf life of Cefuroxime Sodium for Injection vials? The typical shelf life for unopened, intact vials of Cefuroxime Sodium for Injection ranges from 24 to 36 months from the date of manufacture, depending on the specific manufacturer and storage conditions. Once reconstituted, the solution must be used within a specified timeframe, usually a few hours or up to 24 hours under refrigeration, as indicated by the manufacturer's instructions.

3. How does the price of Cefuroxime Sodium for Injection compare to newer generation cephalosporins like Ceftriaxone? Cefuroxime Sodium for Injection is generally less expensive on a per-dose basis than many third-generation cephalosporins like Ceftriaxone. This cost differential is a key factor in its continued use, especially in settings where cost-effectiveness is a primary consideration and the spectrum of Cefuroxime Sodium is adequate for the suspected pathogens.

4. What are the main contraindications for Cefuroxime Sodium for Injection? The primary contraindications include known hypersensitivity to cefuroxime, other cephalosporins, or any component of the formulation. Caution is also advised in patients with a history of severe penicillin allergy, as cross-reactivity can occur.

5. Can Cefuroxime Sodium for Injection be used for long-term outpatient treatment? While Cefuroxime Sodium for Injection is used in hospital settings for moderate to severe infections, it is generally not the preferred agent for routine long-term outpatient treatment due to the need for parenteral administration. Oral formulations of cefuroxime (e.g., cefuroxime axetil) are available for outpatient oral therapy for less severe infections.

Citations

[1] PubChem. (n.d.). Cefuroxime. National Library of Medicine. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Cefuroxime